Disease mongering and low testosterone in men: The tale of two regulatory failures

Medical Journal of Australia

Volumn 196, Issue 10, 2012, Pages 619-621

  Vitry, Agnes I ^a   Mintzes, Barbara ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TESTOSTERONE; ANDROGEN;

ADVERTIZING; AGING; ANDROGEN THERAPY; AUSTRALIA; AWARENESS; CANADA; CARDIOVASCULAR DISEASE; CONSUMER; DISEASE AWARENESS; DRUG INDUSTRY; HEALTH PROMOTION; HELP SEEKING BEHAVIOR; HUMAN; HYPOGONADISM; LIBIDO DISORDER; MEDICAL INFORMATION; NOTE; PRACTICE GUIDELINE; PRESCRIPTION; PROSTATE CANCER; SEXUAL FUNCTION; SYMPTOMATOLOGY; ARTICLE; DRUG CONTROL; HORMONE SUBSTITUTION; INAPPROPRIATE PRESCRIBING; MALE; PHYSIOLOGY; SEXUAL DYSFUNCTION;

ADVERTISING AS TOPIC; AGING; ANDROGENS; AUSTRALIA; CANADA; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; HORMONE REPLACEMENT THERAPY; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE;

EID: 84865076662     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja11.11299     Document Type: Note

References (16)

1. Mackenzie FJ, Jordens CF, Ankeny RA, et al. Direct-to-consumer advertising under the radar: the need for realistic drugs policy in Australia. Intern Med J 2007; 37: 224-228.
2. Mintzes B. Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 2006; 3: e198.
3. 't Jong GW, Stricker BH, Sturkenboom MC. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. BMJ 2004; 328: 931.
4. Brody H, Light DW. The inverse benefit law: how drug marketing undermines patient safety and public health. Am J Public Health 2011; 101: 399-404.
5. Abbott Canada. Not feeling like the man you used to be [advertising campaign]? http://www.lowt.ca/index.php (accessed Oct 2011).
6. Testosterone for "late-onset hypogonadism" in men. Drug Ther Bull 2010; 48: 69-72.
7. Handelsman DJ. Testosterone and male ageing: spinning the wheels. Med J Aust 2010; 193: 379-380.
8. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and metaanalysis. J Clin Endocrinol Metab 2010; 95: 2560-2575.
9. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebocontrolled trials. Mayo Clin Proc 2007; 82: 29-39.
10. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122.
11. Medicines Australia. Code of Conduct. Edition 15. http://medicinesaustralia.com.au/files/2010/01/Code-of-Conduct-Edition-15.pdf (accessed May 2012).
12. Medicines Australia Code of Conduct. Annual report 2011. http:// medicinesaustralia.com.au/files/2010/01/20110829-PUB-CoC-AnnualReport-2010_2011.pdf (accessed May 2012).
13. Medicare Australia. PBS statistics. Canberra: Australian Government Department of Human Services, 2012. http://www.medicareaustralia.gov.au/ provider/pbs/stats.jsp (accessed Jan 2012).
14. Hall DV, Jones SC, Iverson DC. Content analysis of disease awareness advertisements in popular Australian women's magazines. Med J Aust 2009; 191: 625-629.
15. HAI Europe, ISDB, AIM, BEUC, Medicines in Europe Forum. Relevant health information for empowered citizens. Joint Declaration, 2006. http:// english.prescrire.org/Docu/Archive/docus/declarationInfoPatientEN0610.pdf (accessed Oct 2011).
16. World Health Organization. Ethical criteria for medicinal drug promotion. http://whqlibdoc.who.int/publications/1988/924154239X_eng.pdf (accessed May 2012).